MX2024011922A - Nuevo tratamiento para distrofia muscular facioescapulohumeral (fshd) - Google Patents

Nuevo tratamiento para distrofia muscular facioescapulohumeral (fshd)

Info

Publication number
MX2024011922A
MX2024011922A MX2024011922A MX2024011922A MX2024011922A MX 2024011922 A MX2024011922 A MX 2024011922A MX 2024011922 A MX2024011922 A MX 2024011922A MX 2024011922 A MX2024011922 A MX 2024011922A MX 2024011922 A MX2024011922 A MX 2024011922A
Authority
MX
Mexico
Prior art keywords
fshd
muscular dystrophy
facioscapulohumeral muscular
new treatment
facioscapulohumeral
Prior art date
Application number
MX2024011922A
Other languages
English (en)
Spanish (es)
Inventor
Eleni Gaki
Tammy Mciver
Scalco Renata Siciliani
Kathryn Rae Wagner
Wai Yin Yeung
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2024011922A publication Critical patent/MX2024011922A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2024011922A 2022-04-01 2024-09-27 Nuevo tratamiento para distrofia muscular facioescapulohumeral (fshd) MX2024011922A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22166261 2022-04-01
PCT/EP2023/058218 WO2023187022A1 (en) 2022-04-01 2023-03-30 New treatment for facioscapulohumeral muscular dystrophy (fshd)

Publications (1)

Publication Number Publication Date
MX2024011922A true MX2024011922A (es) 2024-11-08

Family

ID=81328333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011922A MX2024011922A (es) 2022-04-01 2024-09-27 Nuevo tratamiento para distrofia muscular facioescapulohumeral (fshd)

Country Status (11)

Country Link
US (1) US20250171526A1 (https=)
EP (1) EP4504779A1 (https=)
JP (1) JP2025511167A (https=)
KR (1) KR20240165959A (https=)
CN (1) CN119053619A (https=)
AU (1) AU2023246859A1 (https=)
CA (1) CA3255735A1 (https=)
IL (1) IL315473A (https=)
MX (1) MX2024011922A (https=)
TW (1) TW202346345A (https=)
WO (1) WO2023187022A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
AR107078A1 (es) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso

Also Published As

Publication number Publication date
AU2023246859A1 (en) 2024-09-05
TW202346345A (zh) 2023-12-01
AU2023246859A9 (en) 2024-09-12
EP4504779A1 (en) 2025-02-12
KR20240165959A (ko) 2024-11-25
JP2025511167A (ja) 2025-04-15
WO2023187022A1 (en) 2023-10-05
IL315473A (en) 2024-11-01
CN119053619A (zh) 2024-11-29
CA3255735A1 (en) 2023-10-05
US20250171526A1 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
MX2021013662A (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
MX2023007852A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
EA202091964A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
CO2022010223A2 (es) Tensioactivos para la producción de petróleo y gas
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
PH12023500023A1 (en) Cdk2 degraders and uses thereof
ECSP23019525A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
CL2025004153A1 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso.
CO2026004176A2 (es) Degradadores de stat6 y usos de los mismos
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
CO2025016192A2 (es) Moléculas y métodos de uso de estas
MX2024011922A (es) Nuevo tratamiento para distrofia muscular facioescapulohumeral (fshd)
CO2025015637A2 (es) Quinoxalinas sustituidas
EP4245374A3 (en) Pvrl2 and/or pvrig as biomarkers for treatment
CO2022019225A2 (es) Anticuerpos anti-hbv y métodos de uso
CL2022000752A1 (es) Molécula de unión específica para lif y uso de la misma
WO2022090801A3 (en) Pvrl2 and/or pvrig as biomarkers for treatment
BR112022009587A2 (pt) Anticorpo anti-pcsk9 e uso do mesmo
CO2024016060A2 (es) Anticuerpos anti-ly6e, inmunoconjugados y usos de estos
MX2025002657A (es) Anticuerpo anti-ilt4 y uso farmaceutico del mismo